Biochemical, structural and functional analysis of a pseudoknot required for hepatitis C virus replication.
Lead Research Organisation:
University of Warwick
Department Name: Biological Sciences
Abstract
Hepatitis C virus infects a predicted 170 million people worldwide and causes chronic liver disease leading to cirrhosis and hepatocellular carcinoma. The virus is transmitted in contaminated blood and by needle-sharing. The virus is highly variable; prior infection does not appear to protect from re-infection and there is no realistic prospect of producing a vaccine. Extended drug treatment can clear the virus in a proportion of those infected, but treatment is expensive and has unpleasant side-effects. To make new and improved therapies we need to understand better how the virus replicates. Our previous studies have identified a small region of the genome that is critical for an early event in virus replication. It is highly conserved in all isolates of this variable virus. We have data to suggest that this element forms a molecular switch controlling two of the earliest events in the virus life cycle ? the translation of the virus to make proteins, and the replication of the virus genome. We propose to continue these studies to define exactly how this switch operates and, in doing so, expect to learn of ways in which we can prevent it from being ?tripped? and so halt the replication of the virus.
Technical Summary
It is important to better understand the replication of hepatitis C virus (HCV) to identify potential new therapeutic targets to which anti-viral therapies can be directed. We have used bioinformatics to predict long-range interactions of structured RNA elements within the HCV genome, and confirmed these interactions by reverse genetic analysis using cell culture replication systems. Our studies suggest the structure forms a complex extended pseudoknot. In other viruses, such structures are implicated in control of translation and genome replication, and we have data that implies that this pseudoknot may have similar functions in HCV. We propose to conduct structural and biochemical studies to determine whether the pseudoknot forms one single structure, or can adopt two alternate configurations that implies it could operate as a molecular switch. We will investigate the interaction of proteins with this pseudoknot and determine their identity. We will rigorously investigate a role for the pseudoknot in virus translation using cell-based studies and will gain further insights into function by analysing replication in the HCV cell culture system. These studies will provide important information on fundamental aspects of the replication cycle of an important human pathogen.
Publications


Tuplin A
(2012)
A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication.
in Nucleic acids research

Tuplin A
(2011)
Replication enhancer elements within the open reading frame of tick-borne encephalitis virus and their evolution within the Flavivirus genus.
in Nucleic acids research

Tuplin A
(2015)
Inhibition of HCV translation by disrupting the structure and interactions of the viral CRE and 3' X-tail.
in Nucleic acids research
Description | Cogent |
Amount | £37,500 (GBP) |
Organisation | Cogent |
Sector | Private |
Country | Guernsey |
Start |
Description | Project grant |
Amount | £483,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2012 |
End | 03/2015 |
Description | Strategic Impact Fund |
Amount | £37,000 (GBP) |
Organisation | University of Warwick |
Sector | Academic/University |
Country | United Kingdom |
Start |
Title | Software |
Description | Software developed by co-applicant (PS) as part of this proposal. |
Type Of Material | Technology assay or reagent |
Year Produced | 2007 |
Provided To Others? | Yes |
Impact | In our laboratory - software has provided important insights into RNA structures in HCV and many other viruses. This software has enabled a number of new projects to be initiated - including studies on recombination (funded by the Wellcome Trust) and the role of RNA structures in subversion of the innate immune responses (funding obtained, but not yet initiated). In other laboratories - software has been downloaded over 300 times, but use and application has not been recorded. |
Description | CJ |
Organisation | University of Nottingham |
Department | School of Biomedical Sciences Nottingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Developed system to investigate translational control in hepatitis C virus and the influence of micro-RNA on this process. |
Collaborator Contribution | Intellectual and contribution of reagents |
Impact | Successful MRC grant application |
Start Year | 2010 |
Description | EA |
Organisation | University of Oxford |
Department | Department of Chemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Developed methods to study long-range interactions of RNA |
Collaborator Contribution | Intellectual |
Impact | Successful grant application using this approach. Multi-disciplinary - chemistry and biology/virology. Additional grant application with this collaborator in which I am the external collaborator. |
Start Year | 2009 |
Description | JL |
Organisation | University of Edinburgh |
Department | School of Chemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Devised new way of detecting long-range RNA interactions |
Collaborator Contribution | Intellectual and - in due course - experimental. |
Impact | Successful MRC grant application. Multi-disciplinary - chemistry and biology/virology. Additional collaborations on other research council grant applications. |
Start Year | 2009 |
Title | INHIBITOR FOR TREATMENT OF HCV |
Description | Therapeutic target identified and inhibitors designed |
IP Reference | WO2014155097 |
Protection | Patent application published |
Year Protection Granted | |
Licensed | Commercial In Confidence |
Impact | PhD. funding from Cogent Ltd. |